Polysorbate 80 n f

Δ⁹-THC, JWH-018, JWH-073, JWH-081, JWH-210, rimonabant, and SR144528 were obtained from the National Institute on Drug Abuse (NIDA, Bethesda, MD) through the NIDA Drug Supply Program. JWH-167 and JWH-391 were synthesized by John Huffman (Clemson University, Clemson, SC). AM-2201 was purchased from Cayman Chemical (Ann Arbor, MI). For in vivo administration, all cannabinoid compounds were dissolved in a vehicle of 7.8% Polysorbate 80 N.F. (VWR, Marietta, GA) and 92.2% sterile saline USP (Butler Schein, Dublin, OH). Mianserin HCl was obtained from Sigma Aldrich (St. Louis, MO) and was dissolved in sterile saline USP. All compounds used in the FOB procedure were administered intravenously (i.v.) into the tail vein at a volume of 10 ml/kg. Details of compound administration for the drug discrimination procedure are presented in section 2.6.

Δ⁹-Tetrahydrocannabinol [THC] [National Institute on Drug Abuse (NIDA), Bethesda, MD] and WIN55,212-2 (Cayman Chemical, Ann Arbor, MI) were suspended in a vehicle of 1% Polysorbate 80 N.F. (VWR, Radnor, PA) and sterile saline USP (Butler Schein, Dublin, OH). Rimonabant [SR141716] (NIDA) was suspended in a vehicle of 7.8% Polysorbate 80 and sterile saline. Concentrated stock solutions of WIN55,212-2 and THC were suspended in a vehicle of 1% Polysorbate 80 and sterile saline, and this same vehicle of 1% Polysorbate 80 and sterile saline was used to dilute the stock solutions. When formulating THC, all ethanol was evaporated off prior to making the concentrated stock solutions. Syringes were kept in a dark refrigerator when not in use during the self-administration sessions to avoid exposure to light. Solutions of all drugs were used for a maximum of one month after initial formulation to avoid degradation. Doses of all drugs are expressed as mg/kg of the base. WIN55,212-2 and THC were administered to the rats intravenously by infusion. Rimonabant was injected intraperitoneally (i.p.) at a volume of 1 ml/kg 30 min prior to the start of the session. Pre-session injection time was based upon our previous experience with this compound. Post-flush solution components, gentamicin USP and heparin USP, were purchased from Butler Schein.

THC [National Institute on Drug Abuse (NIDA), Bethesda, MD, USA] and rimonabant (NIDA) were suspended in a vehicle of 7.8 % Polysorbate 80 N.F. (VWR, Radnor, PA, USA) and 92.2% sterile saline USP (Butler Schein, Dublin, OH, USA). Doses of THC and rimonabant were administered at a volume of 1 ml/kg. Ketamine (Fort Dodge, Fort Dodge, IA) and xylazine (Lloyd Laboratories, Shenandoah, IA) were diluted with sterile saline USP, and the cocktail was administered at a volume of 3 ml/kg. P4 (Steraloids, Newport, RI, USA) was dissolved in safflower oil USP (Spectrum Chemical, Gardena, CA, USA). E2 and T (Steraloids, Newport, RI, USA) were administered through Silastic capsules assembled in-house (c.f. Stoffel et al., 2003 (link)).